Eli Lilly’s limited October 2024 research-only agreement with Peptron, which grants non-exclusive evaluation rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release but no commercial manufacturing or sales rights, remains the dominant factor behind the 87.5% “No” odds. Nearly two years later, no technology-transfer or licensing deal has materialized, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent reporting on Lilly’s pivot toward oral obesity candidates has further cooled expectations for near-term commercial expansion of the Peptron collaboration. With roughly seven weeks until the October 7 resolution date and no credible catalysts signaling an imminent binding agreement, traders view a last-minute licensing announcement as improbable.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於13% 機率
$11,264 交易量
$11,264 交易量
2026-10-07
13% 機率
$11,264 交易量
$11,264 交易量
2026-10-07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s limited October 2024 research-only agreement with Peptron, which grants non-exclusive evaluation rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release but no commercial manufacturing or sales rights, remains the dominant factor behind the 87.5% “No” odds. Nearly two years later, no technology-transfer or licensing deal has materialized, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent reporting on Lilly’s pivot toward oral obesity candidates has further cooled expectations for near-term commercial expansion of the Peptron collaboration. With roughly seven weeks until the October 7 resolution date and no credible catalysts signaling an imminent binding agreement, traders view a last-minute licensing announcement as improbable.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市場開放時間： May 5, 2026, 8:02 PM ET
交易量
$11,264結束日期
2026-10-07市場開放時間
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s limited October 2024 research-only agreement with Peptron, which grants non-exclusive evaluation rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release but no commercial manufacturing or sales rights, remains the dominant factor behind the 87.5% “No” odds. Nearly two years later, no technology-transfer or licensing deal has materialized, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent reporting on Lilly’s pivot toward oral obesity candidates has further cooled expectations for near-term commercial expansion of the Peptron collaboration. With roughly seven weeks until the October 7 resolution date and no credible catalysts signaling an imminent binding agreement, traders view a last-minute licensing announcement as improbable.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$11,264結束日期
2026-10-07市場開放時間
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s limited October 2024 research-only agreement with Peptron, which grants non-exclusive evaluation rights to the SmartDepot ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release but no commercial manufacturing or sales rights, remains the dominant factor behind the 87.5% “No” odds. Nearly two years later, no technology-transfer or licensing deal has materialized, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent reporting on Lilly’s pivot toward oral obesity candidates has further cooled expectations for near-term commercial expansion of the Peptron collaboration. With roughly seven weeks until the October 7 resolution date and no credible catalysts signaling an imminent binding agreement, traders view a last-minute licensing announcement as improbable.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions